Cart
sales@molnova.com
Lapatinib
CAS No. 231277-92-2
Lapatinib ( GW572016;GW-572016;GW 572016 )
Catalog No. M13650 CAS No. 231277-92-2
A reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 35 | In Stock |
|
| 50MG | 45 | In Stock |
|
| 100MG | 60 | In Stock |
|
| 200MG | 76 | In Stock |
|
| 500MG | 116 | In Stock |
|
| 1G | 133 | In Stock |
|
Biological Information
-
Product NameLapatinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
DescriptionA reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively; displays no significant activity against other kinases, including ErbB4, c-Src, and c-Raf1; reduces tyrosine phosphorylation of EGFR and erbB2, and inhibits activation of Erk1/2 and AKT both in vitro and in vivo; inhibits tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg; orally active.Breast Cancer Approved
-
SynonymsGW572016;GW-572016;GW 572016
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorC-Raf-1;c-Src;EGFR;HER2/ErbB2
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number231277-92-2
-
Formula Weight581.06
-
Molecular FormulaC29H26ClFN4O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 39 mg/mL
-
SMILESCS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
-
Chemical Name4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xia W, et al. Oncogene. 2002 Sep 12;21(41):6255-63.
2. Rusnak DW, et al. Mol Cancer Ther. 2001 Dec;1(2):85-94.
3. Konecny GE, et al. Cancer Res. 2006 Feb 1;66(3):1630-9.
2. Rusnak DW, et al. Mol Cancer Ther. 2001 Dec;1(2):85-94.
3. Konecny GE, et al. Cancer Res. 2006 Feb 1;66(3):1630-9.
molnova catalog
related products
-
Theliatinib
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
-
AZD-3759
A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
